Targeting chemoresistance and mitochondria-dependent metabolic reprogramming in acute myeloid leukemia is a research paper published in Frontiers in Oncology (2023). On theSindex it has a DataRank of 0. It has been cited 13 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
NCI NIH HHS
Grant: R21 CA164970
NCI NIH HHS
Grant: R21 CA221702
NIDDK NIH HHS
Grant: R01 DK108894
National Institutes of Health
Grant: 5R01DK108894-05
Immunomodulatory effects of bilirubin are mediated through aryl hydrocarbon receptor, O2 and purinergic pathways
National Institutes of Health
Grant: 5R21CA164970-02
Engineering Inhibitory Antibodies to Ectoenzymes for Cancer Treatment
National Institutes of Health
Grant: 1R21CA221702-01A1
Directed Purinergic Signaling as Immunotherapy in Leukemia
FWCI
2.75
Citation Percentile
0.9%
Citation Trend
Fields of Study
Keywords
Sustainable Development Goals